HSBC Holdings plc Reiterates “GBX 4,500” Price Target for AstraZeneca plc (AZN)

HSBC Holdings plc set a GBX 4,500 ($58.15) price target on AstraZeneca plc (LON:AZN) in a report published on Tuesday. The firm currently has a sell rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on AZN. Barclays PLC reissued an overweight rating and set a GBX 6,000 ($77.53) price objective on shares of AstraZeneca plc in a report on Monday. JPMorgan Chase & Co. reissued a neutral rating on shares of AstraZeneca plc in a report on Monday. Deutsche Bank AG reissued a buy rating and set a GBX 5,700 ($73.65) price objective on shares of AstraZeneca plc in a report on Monday. Liberum Capital reissued a buy rating and set a GBX 5,500 ($71.07) price objective on shares of AstraZeneca plc in a report on Monday. Finally, Kepler Capital Markets reissued a buy rating and set a GBX 5,500 ($71.07) price objective on shares of AstraZeneca plc in a report on Monday. Six analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of GBX 5,041.80 ($65.15).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON AZN) opened at 5314.00 on Tuesday. The firm’s 50 day moving average is GBX 4,977.18 and its 200-day moving average is GBX 4,643.62. The company’s market capitalization is GBX 67.28 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.mideasttime.com/hsbc-holdings-plc-reiterates-gbx-4500-price-target-for-astrazeneca-plc-azn/1765354.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.